CHONGQING, CHINA - APRIL 23: In this photo illustration, the logo of Pfizer Inc. is displayed on a smartphone screen, with a stock market chart visible in the background, reflecting trading activity ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer gets you most of the way to 10%. If you buy Pfizer and collect that 6.4% dividend yield, you are roughly two-thirds of ...

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as one of the main vaccine suppliers. That led to its stock price and revenue ...

Pfizer has a long history of success in the competitive and complex drug sector. The pharmaceutical giant has patent expirations coming in 2027 and 2028. Management's attempt to solve the issue has ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical ...

The stock offers a lofty 6.2% yield, and management has declared its intent to support its dividend. The pharmaceutical giant has fallen behind competitors, but is making aggressive moves to catch up.

Pfizer's 7.45% forward dividend yield is misleading, as the share price decline outpaces the payout. Weak dividend growth, stagnant EPS projections, and a looming patent cliff are significant bearish ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...